PE20090041A1 - Derivados de triazol como inhibidores de la biosintesis de leucotrienos - Google Patents

Derivados de triazol como inhibidores de la biosintesis de leucotrienos

Info

Publication number
PE20090041A1
PE20090041A1 PE2008000245A PE2008000245A PE20090041A1 PE 20090041 A1 PE20090041 A1 PE 20090041A1 PE 2008000245 A PE2008000245 A PE 2008000245A PE 2008000245 A PE2008000245 A PE 2008000245A PE 20090041 A1 PE20090041 A1 PE 20090041A1
Authority
PE
Peru
Prior art keywords
inhibitors
ona
triazol
propyl
hydroxy
Prior art date
Application number
PE2008000245A
Other languages
English (en)
Inventor
Yves Ducharme
Richard Friesen
Marc Gagnon
Yves Gareau
Erich L Grimm
Bruce Mackay
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of PE20090041A1 publication Critical patent/PE20090041A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION DE FORMULA (Ib), DONDE A ES UN ANILLO AROMATICO DE 5 MIEMBROS CON 1 A 2 HETEROATOMOS, TALES COMO N, O Y S, PIRIDINILO O FENILO; Y ES -CH2- O -CH2CH2-; R1 ES H, ALQUILO C1-C6 O CICLOALQUILO C3-C6; R2 ES H, OH, F, ALQUILO C1-C3, ENTRE OTROS; R3 Y R4 SON H O ALQUILO C1-C6 SUSTITUIDOS POR FENILO, CICLOALQUILO C3-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(3-FLUOROFENIL)-7-({4-[1-HIDROXI-1-(TRIFLUOROMETIL)PROPIL]-1H-1,2,3-TRIAZOL-1-IL}METIL)-2H-CROMEN-2-ONA, 7-({4-[1-HIDROXI-1-(TRIFLUOROMETIL)PROPIL]-1H-1,2,3-TRIAZOL-1-IL}METIL)-4-(2-METIL-1,3-TIAZOL-4-IL)-2H-CROMEN-2-ONA, 4-(4-FLUOROFENIL)-7-[4-(1-HIDROXI-1-TRIFLUOROMETIL-PROPIL)-[1,2,3]TRIAZOL-1-ILMETIL]-CROMEN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA BIOSINTESIS DE LEUCOTRIENOS Y SON UTILES EN EL TRATAMIENTO DE ATEROSCLEROSIS, ASMA, RINITIS ALERGICA, ENTRE OTROS
PE2008000245A 2007-02-05 2008-02-04 Derivados de triazol como inhibidores de la biosintesis de leucotrienos PE20090041A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89947107P 2007-02-05 2007-02-05
US90035307P 2007-02-08 2007-02-08

Publications (1)

Publication Number Publication Date
PE20090041A1 true PE20090041A1 (es) 2009-02-07

Family

ID=39676707

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000245A PE20090041A1 (es) 2007-02-05 2008-02-04 Derivados de triazol como inhibidores de la biosintesis de leucotrienos

Country Status (12)

Country Link
US (1) US7960409B2 (es)
EP (1) EP2118093B1 (es)
JP (1) JP5514554B2 (es)
CN (1) CN101657443B (es)
AR (1) AR065093A1 (es)
AT (1) ATE550336T1 (es)
AU (1) AU2008213767B2 (es)
CA (1) CA2676498A1 (es)
CL (1) CL2008000307A1 (es)
PE (1) PE20090041A1 (es)
TW (1) TW200838511A (es)
WO (2) WO2008095293A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120578A1 (en) * 2008-11-07 2010-05-13 Hichem Bouguerra Drive and steering control system for an endless track vehicle
CN102050809B (zh) * 2009-11-03 2014-12-17 中国医学科学院药物研究所 拮抗cklf1/ccr4相互作用的3-哌嗪基香豆素衍生物
AU2012329098B2 (en) 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CN104010504B (zh) * 2011-11-03 2016-04-06 默沙东公司 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
KR20160068948A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyt의 이차 알코올 퀴놀리닐 조절제
WO2017049871A1 (zh) * 2015-09-24 2017-03-30 四川大学 4位取代的香豆素衍生物及其制备方法和用途
EP3519416B1 (en) 2016-09-27 2021-03-31 Merck Sharp & Dohme Corp. Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
MY201080A (en) * 2017-07-14 2024-02-03 Innate Tumor Immunity Inc Nlrp3 modulators
CN108299369B (zh) * 2018-01-15 2021-07-30 安徽师范大学 香豆素-4-磺酸酯衍生物及其制备方法
CA3118752A1 (en) * 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
HUE070525T2 (hu) 2019-04-16 2025-06-28 Vivace Therapeutics Inc Biciklusos vegyületek
CN110038012B (zh) * 2019-05-30 2021-06-11 济南大学 具有1,2,3-三氮唑结构片段的生物碱化合物在制备促血管生成药物中的应用
WO2023034340A1 (en) * 2021-08-30 2023-03-09 Pretzel Therapeutics, Inc. Hydroxy and alkoxy coumarins as modulators of polrmt
US20250326732A1 (en) * 2021-08-30 2025-10-23 Pretzel Therapeutics, Inc. Chromen-2-one modulators of polrmt
CN114307937B (zh) * 2022-02-24 2024-05-24 辽宁博仕科技股份有限公司 基于射流反应器的过一硫酸氢钾复合盐生产装置及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424320A (en) * 1993-06-23 1995-06-13 Merck Frosst Canada, Inc. Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
US5410054A (en) 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5552437A (en) * 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
JP2006527207A (ja) * 2003-06-11 2006-11-30 メルク フロスト カナダ リミテツド ７−（１，３−チアゾール−２−イル）チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用
WO2007016784A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.

Also Published As

Publication number Publication date
AR065093A1 (es) 2009-05-13
US7960409B2 (en) 2011-06-14
JP2010517947A (ja) 2010-05-27
WO2008095293A1 (en) 2008-08-14
EP2118093A1 (en) 2009-11-18
WO2008095292A1 (en) 2008-08-14
CN101657443B (zh) 2013-10-23
AU2008213767B2 (en) 2013-06-06
CN101657443A (zh) 2010-02-24
TW200838511A (en) 2008-10-01
EP2118093B1 (en) 2012-03-21
AU2008213767A1 (en) 2008-08-14
JP5514554B2 (ja) 2014-06-04
US20080188521A1 (en) 2008-08-07
CL2008000307A1 (es) 2008-05-30
EP2118093A4 (en) 2010-03-17
ATE550336T1 (de) 2012-04-15
CA2676498A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
PE20090041A1 (es) Derivados de triazol como inhibidores de la biosintesis de leucotrienos
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20141059A1 (es) Indazoles
PE20091816A1 (es) Inhibidores de bace
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20140909A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
NZ594323A (en) Compositions and methods for inhibition of the jak pathway
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20141120A1 (es) Compuestos heterociclicos
PE20141033A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20061123A1 (es) Derivados de amida como inhibidores de la hidrolasa de amida de acido graso
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
NZ600801A (en) Substituted imidazopyridinyl-aminopyridine compounds
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
MY148643A (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives

Legal Events

Date Code Title Description
FD Application declared void or lapsed